Ceritinib inALK-Rearranged Non–Small-Cell Lung Cancer
Authors:
- Alice T. ShawASAlice T. Shaw
- Dong-Wan KimDKDong-Wan Kim
- Ranee MehraRMRanee Mehra
- Daniel S.W. TanDTDaniel S.W. Tan
- Enriqueta FelipEFEnriqueta Felip
- Laura Q.M. ChowLCLaura Q.M. Chow
- D. Ross CamidgeDCD. Ross Camidge
- Johan VansteenkisteJVJohan Vansteenkiste
- Sunil SharmaSSSunil Sharma
- Tommaso De PasTPTommaso De Pas
- Gregory J. RielyGRGregory J. Riely
- Benjamin J. SolomonBSBenjamin J. Solomon
Top Cited Papers
- 27 March 2014
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 370 (13) , 1189-1197
Abstract
Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies. In this phase 1 study, we administered oral ceritinib in doses of 50 to 750 mg once daily to patients with advanced cancers harboring genetic alterations in ALK. In an expansion phase of the study, patients received the maximum tolerated dose. Patients were assessed to determine the safety, pharmacokinetic properties, and antitumor activity of ceritinib. Tumor biopsies were performed before ceritinib treatment to identify resistance mutations in ALK in a group of patients with NSCLC who had had disease progression during treatment with crizotinib. A total of 59 patients were enrolled in the dose-escalation phase. The maximum tolerated dose of ceritinib was 750 mg once daily; dose-limiting toxic events included diarrhea, vomiting, dehydration, elevated aminotransferase levels, and hypophosphatemia. This phase was followed by an expansion phase, in which an additional 71 patients were treated, for a total of 130 patients overall. Among 114 patients with NSCLC who received at least 400 mg of ceritinib per day, the overall response rate was 58% (95% confidence interval [CI], 48 to 67). Among 80 patients who had received crizotinib previously, the response rate was 56% (95% CI, 45 to 67). Responses were observed in patients with various resistance mutations in ALK and in patients without detectable mutations. Among patients with NSCLC who received at least 400 mg of ceritinib per day, the median progression-free survival was 7.0 months (95% CI, 5.6 to 9.5). Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT01283516.)Keywords
This publication has 26 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- ALK in Lung Cancer: Past, Present, and FutureJournal of Clinical Oncology, 2013
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion GeneAnnals of Surgical Oncology, 2009
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western PopulationClinical Cancer Research, 2009
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor PathwayClinical Lung Cancer, 2009
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung TissuesThe American Journal of Pathology, 2009
- EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung CancerClinical Cancer Research, 2008
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005